VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

Peter Voorhees, MD
Published: Friday, Apr 27, 2018



Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 


Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x